Printer Friendly

BIOCONTROL TECHNOLOGY FDA APPLICATION FOR DIASENSOR 1000

 /NOTE TO EDITORS: According to Biocontrol Technology, the following release was issued by the company on Jan. 6 by fax and by mail. This is the first transmission of the release on PR Newswire./
 PITTSBURGH, Jan. 6 /PRNewswire/ -- Biocontrol Technology, Inc. (NASDAQ: BICO) announced today that it has filed a 510(k) Notification to the Food and Drug Administration for the purpose of market approval for Diasensor 1000, its non-invasive glucose sensor.
 A 510(k) is simply a pre-market notification that requires a manufacturer to demonstrate that its machine is equal to or better than the glucose monitors that are now being marketed.
 "Our long awaited machine is truly a technological breakthrough," said Fred E. Cooper, Chief Executive Officer of Biocontrol Technology, Inc. "Literally thousands of diabetics have been waiting patiently for the Diasensor 1000 to come on the market, because the non-invasive sensor will eliminate the need to draw blood as must be done with any glucose monitor presently on the market. This pain and inconvenience caused by using these currently existing monitors have created a tremendous demand for our sensor."
 Cooper further stated, "The man who is responsible for this idea and this wonderful technology is David L. Purdy, President of Biocontrol Technology, Inc. His vision in 1985 has brought this non-invasive testing technology to a new horizon. There are many other blood constituents, such as cholesterol and alcohol, that can be tested much easier than the glucose molecule. Therefore, non-invasive testing will be the wave of the future.
 "Since Diasensor 1000 is a Class 2 device, which is intended for human use but is not life-sustaining or life-supporting, we anticipate that the approval process should take no longer than 90 to 120 days. At the present time, we are commencing with our manufacturing start-up. It will take four to five months to get our Indiana, Pa., facility ready to begin production of the sensors by late spring," concluded Cooper.
 Biocontrol has an exclusive manufacturing agreement with Diasense, Inc., of Pittsburgh, which owns the sensor technology. Diasense will purchase the sensors from Biocontrol Technology, Inc. and market them worldwide.
 Biocontrol Technology, Inc. is headquartered in Indiana, Pennsylvania, with administrative offices in Pittsburgh, and is involved in the development and manufacture of biomedical and bioremediation technology.
 -0- 1/12/94
 /CONTACT: media, Susan Taylor, 412-279-9455, or fax, 412-279-9447, or investors, Diane McQuaide, 412-429-0673, or fax, 412-279-1367, both of Biocontrol Technology/
 (BICO)


CO: Biocontrol Technology, Inc. ST: Pennsylvania IN: MTC SU: PDT

CD-JM -- PG001 -- 1263 01/12/94 08:05 EST
COPYRIGHT 1994 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1994 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 12, 1994
Words:421
Previous Article:MERRY-GO-ROUND BANKRUPTCY NEWS: THE BY-FAX NEWSLETTER
Next Article:AIR METHODS INCORPORATES FIRST-OF-ITS KIND INTERNATIONAL AIR MEDICAL JOINT VENTURE TO BE LAUNCHED IN MEXICO CITY
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters